Denis Chem Lab Q1 FY27 results: revenue up 1.7% YoY, PAT falls 17%

EBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.1%Reaction day

₹68.13

prior close

₹71.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+3.9% vs market

Pharmaceuticals peers, median of 166sector+0.1%+4.0% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.7

10m

-0.7

15m

-0.7

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.1+0.2+3.9+0.1+4.0

Next day

+4.1+0.2+3.8-0.3+4.3

+4.5+0.4+4.2-0.2+4.7

+5.1+0.7+4.4-0.4+5.5

+4.6+0.1+4.4-1.5+6.0

+4.2+0.7+3.5-0.9+5.1

+5.7+1.2+4.5-0.6+6.3

15d

+3.6+0.7+2.9+0.3+3.3

+3.3-1.2+4.5-0.2+3.4

-6.1-1.1-5.0-2.3-3.9

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Denis Chem Lab posted Q1 FY27 (quarter ended 30 June 2026) revenue from operations of Rs 4,399.67 lakh, up 1.7% from Rs 4,327.59 lakh YoY but down about 6% from Q4 FY26 at Rs 4,675.49 lakh. Profit after tax was Rs 204.52 lakh versus Rs 247.50 lakh YoY, a 17% decline. EPS stood at Rs 1.47 versus Rs 1.78. Operating profit margin (PBT plus depreciation over revenue) compressed to around 9.5% from 11.4% YoY due to higher other expenses. Company carries zero financial debt and has no defaults. Auditor issued an unmodified limited review opinion.

Likely market impact

Mixed picture: top line steady but PAT and margins slipped. Zero debt remains a strength. Watch margin recovery.